Durect Posts Narrower Loss in Fiscal Q2

Durect (NASDAQ:DRRX) reported better-than-expected Q2 2025 GAAP EPS of $(0.07) and revenue of $0.45 million, surpassing analyst estimates despite a 31% year-over-year revenue decline and a significant drop in cash to $6.7 million. The biopharmaceutical company's financial results reflect ongoing operational cuts and highlight its critical dependence on the lead drug candidate, larsucosterol, for which no new clinical data was released. The company's immediate future is now primarily defined by its pending acquisition by Bausch Health for $1.75 per share plus potential milestones, underscoring strategic uncertainty and financial risk ahead of the expected Q3 2025 close.

Analysis

Durect's (DRRX) second-quarter 2025 results present a mixed but ultimately concerning financial picture, overshadowed by its pending acquisition by Bausch Health. While the company reported a notable beat on analyst expectations with a GAAP EPS of $(0.07) against a $(0.13) forecast and revenue of $0.45 million versus a $0.32 million consensus, these figures mask significant underlying weakness. Year-over-year revenue plummeted 31% from $0.65 million, and the company's cash position has deteriorated to a precarious $6.7 million. Operational metrics confirm a company in preservation mode, with R&D expenses cut by 48% and SG&A by 20% year-over-year, signaling a halt in standalone strategic initiatives. The lack of new clinical data for its pivotal asset, larsucosterol, and the absence of any forward guidance from management reinforce that Durect's focus has shifted entirely to completing the merger. The company's financial performance is now secondary to the transaction's terms: $1.75 per share in cash plus potential sales milestones, making the deal's closure the sole driver of near-term shareholder value.

Key Decisions for Investors

• The primary investment thesis for Durect is now an M&A arbitrage play; investors should focus on the probability and timing of the Bausch Health acquisition closing at the agreed $1.75 per share price, rather than on the company's standalone fundamentals.
• Monitor the cash position of $6.7 million closely, as any delay or failure of the acquisition could create significant solvency risk and necessitate dilutive financing.
• Shareholders should value their positions based on the certain $1.75 cash consideration plus their individual assessment of achieving the contingent sales milestones for larsucosterol post-acquisition.
• Given the strategic pivot to the merger, declining revenues, and halt in R&D momentum, there is little basis for a long-term investment in Durect as a standalone entity; the investment case is almost entirely dependent on the merger's completion in Q3 2025.